Results 1 to 10 of about 756 (101)

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Frontiers in Pharmacology, 2023
Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-
Huqun Li, Chongshu Wang, Aiping Deng, Cuilian Guo   +3 more
doaj   +1 more source

Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review

Respirology Case Reports, 2023
Mepolizumab, a humanized anti‐IL‐5 monoclonal antibody used for severe asthma, results in a reduced rate of asthma exacerbation, improved lung function, reduced oral corticosteroid use, and improved quality of life.
Takahiro Matsuyama, Yuya Tomioka, Hiromi Matsuyama, Yusuke Kamenohara, Kengo Tanigawa, Yoichi Dotake, Yoko Hagihara, Koichi Takagi, Kentaro Machida, Hiromasa Inoue   +9 more
doaj   +1 more source

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis

Allergy, Asthma & Clinical Immunology, 2023
Background The mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is systemic corticosteroid therapy; some patients also receive intravenous immunoglobulins, other immunosuppressive agents, and biologics.
Nami Masumoto, Chiyako Oshikata, Ryo Nakadegawa, Yuto Motobayashi, Reeko Osada, Saki Manabe, Takeshi Kaneko, Naomi Tsurikisawa   +7 more
doaj   +1 more source

Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma

Frontiers in Pharmacology, 2023
Oral corticosteroids (OCS) are commonly used for the acute management of severe asthma exacerbations or as maintenance therapy; however, chronic use is associated with significant toxicities, e.g., osteoporosis. In the REal worlD Effectiveness and Safety
Christian Domingo, Christian Domingo, Ana Sogo, Ana Sogo, Enrique Casado, Eva Martínez-Moragón, Marina Blanco-Aparicio, Teresa Carrillo, Teresa Carrillo, David Bañas-Conejero, María-Guadalupe Sánchez-Herrero   +10 more
doaj   +1 more source

Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype

Biomedicines, 2022
Severe asthma (SA) is categorized into multiple overlapping phenotypes and clinical characteristics driven by complex mechanistic inflammatory pathways. Mepolizumab is a human monoclonal antibody effectively targeting interleukin-5 in severe eosinophilic
Ruperto González-Pérez, Paloma Poza-Guedes, Elena Mederos-Luis, Inmaculada Sánchez-Machín   +3 more
doaj   +1 more source

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials

Health Sciences Review, 2023
Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj   +1 more source

Use of Mepolizumab in Children and Adolescents with Asthma in the USA

Journal of Respiration, 2022
Introduction: Pediatric asthma affects 5.5 million US children and is the leading cause of pediatric chronic illness globally. Those with severe asthma have significantly higher healthcare costs compared to those with non-severe disease.
Jaclyn Davis, Pamela M. McMahon, Emily Welch, Cheryl McMahill-Walraven, Aziza Jamal-Allial, Tancy Zhang, Christine Draper, Anne Marie Kline, Leslie Koerner, Jeffrey S. Brown, Melissa Van Dyke, Ann Chen Wu   +11 more
doaj   +1 more source

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

Frontiers in Immunology, 2023
BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia.ObjectiveTo assess the effectiveness and safety of mepolizumab (anti-IL-5) and ...
Santi Nolasco, Santi Nolasco, Andrea Portacci, Raffaele Campisi, Enrico Buonamico, Corrado Pelaia, Alida Benfante, Massimo Triggiani, Giuseppe Spadaro, Maria Filomena Caiaffa, Giulia Scioscia, Aikaterini Detoraki, Giuseppe Valenti, Francesco Papia, Alessandra Tomasello, Nunzio Crimi, Nicola Scichilone, Girolamo Pelaia, Giovanna Elisiana Carpagnano, Claudia Crimi, Claudia Crimi   +20 more
doaj   +1 more source

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

Respiratory Medicine Case Reports, 2019
We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-
Osamu Matsuno, Seijiro Minamoto
doaj   +1 more source

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Allergy, Asthma & Clinical Immunology, 2021
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian, Jane Jiyoon Park, Michael W. Tsoulis, Harold Kim   +3 more
doaj   +1 more source